Finland-based Valo Therapeutics Oy has raised €11 million in an over-subscribed financing round to support a first clinical trial of it lead cancer drug – an antigen-coated oncolytic virus. The financing, announced on 15 November, was led by the corporate advisory firm Ironside Capital. Existing investor Freeman Road Pty Ltd participated in the round as did new investor MMJ Group Holdings of Australia. The round is being described as a prelude to an initial public share offering.
